Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Patient and occupational safety

CN27 - Occupational safety of oncology nurses handling systemic anti-cancer therapies in Germany


22 Sep 2021


Patient and occupational safety


Matthias Naegele


Annals of Oncology (2021) 32 (suppl_5): S1267-S1269. 10.1016/annonc/annonc694


M.B. Naegele

Author affiliations

  • Comprehensive Cancer Center Zürich, University Hospital Zürich, 8091 - Zürich/CH


Login to access the resources on OncologyPRO.

Abstract CN27


Oncology nurses who handle systemic anti-cancer therapies (SACT) are at a greater health risk due to the cancerogenic, mutagenic, and teratogenic effects of SACT on their own bodies. Many legal requirements aim to protect them from these occupational risks. The aim of this study was to describe the reality of occupational safety of German oncology nurses.


During SACT training courses across Germany, participants were asked whether they themselves had symptoms that they attributed to dealing with SACT. They were also asked about the security measures in place in their institutions. The survey was carried out with the Mentimeter® app.


Between 2017 and 2019, a total of 400 oncology nurses took part in the survey. The majority of 39% had 5-10 years of experience with SACT. One third of the participants reported symptoms from handling SACT, 57% in the last two years. The most common symptoms were skin reactions (53%), headache (41%), and taste sensations (28%). The most common reason for this was skin contact with the SACT due to leaks in the infusion bag or system. None of the recommended security measures were implemented in all institutions. The most common measures were preparing the SACT in the pharmacy (90%), in plastic bags and not in glass bottles (82%) and each individually shrink-wrapped (78%). Special SACT infusion systems were used in 62%. Environmental monitoring (10%) and biomonitoring (2%) was rarely carried out. Participants rated their own adherence to safety measures with 87%, those of other nurses with 76%, physicians with 61%, and cleaning staff with 57%.


The number of German oncology nurses who have reported symptoms on their own bodies is alarming. To improve this situation, the known safety measures must urgently be implemented, and the knowledge of the oncology nurses expanded.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Matthias Hellberg-Naegele.


Has not received any funding.


The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.